Advancing Medicine Through Clinical Research
At the forefront of innovation, Dr. Kuhadiya leads a comprehensive clinical research program dedicated to exploring tomorrow’s therapies today. Under his leadership, DECON is proud to conduct cutting-edge clinical trials that bring promising new treatments directly to our patients and community—often years before these therapies receive FDA approval or become commercially available.
These research trials offer more than just early access to advanced care. They provide hope, progress, and the possibility of better outcomes for individuals facing complex medical conditions. By participating in these studies, patients not only contribute to the advancement of medicine but also receive care guided by the latest scientific insight.
Our team of dedicated providers actively engages in every step of the research process. This hands-on involvement sharpens their clinical expertise, enriches their role as educators, and ensures that the care we provide is both informed by evidence and inspired by innovation. At DECON, clinical research is not a side pursuit—it is a vital part of how we heal, teach, and lead.
Benefits For Our Clinical Trial Patients
- FDA-approved Clinical Trials
- Choose a study: Diabetes, Thyroid, and more
- Adheres to industry safety regulations
- You will be compensated for your time and travel
- HIPAA-compliant
- Full confidentiality
- Complimentary study-related medicines
- Complimentary consultation and medical exam
- Complimentary lab reports
- Guaranteed monetary compensation
Active Clinical Research Trials
- Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes:A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study(CATT1)
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
- REVEAL -1 Study: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)
- REVEAL- 2 Study: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)
- A randomized, open-label study evaluating the safety, tolerability and pharmacokinetics of VRDN-003 administered subcutaneously in participants with Thyroid Eye Disease (TED)